Based upon recent preclinical study data, Astellas Pharma Inc. has terminated the research and development of gene therapy programs AT702, AT751 and AT753 for Duchenne muscular dystrophy.

Unfortunately, their non-clinical research with these three programs did not provide enough evidence of dystrophin rescue at levels that would sufficiently benefit patients. These results significantly delay the timeline to bring the programs to the clinic, creating challenges to the future success of these programs. Their researchers are looking to publish and share their lessons learned with the wider scientific community and have said they plan to continue to seek a path forward in developing a treatment for Duchenne.

We will keep you notified of any further developments regarding this news.